Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2023

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2023 and 2022 is as follows:


	Year Ended March 31, 2023
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2022	$	2,476,559	$	436,174	$	2,912,733



Tradename impairment	(298,664)		(22,748)		(321,412)
Effects of foreign currency exchange rates	(8,993)		(2,308)		(11,301)
Balance – March 31, 2023	$	2,168,902	$	411,118	$	2,580,020

Accumulated Amortization
Balance – March 31, 2022	$	—	$	216,098	$	216,098
Additions	—		22,266		22,266

Effects of foreign currency exchange rates	—		(237)		(237)
Balance – March 31, 2023	$	—	$	238,127	$	238,127

Intangible assets, net – March 31, 2023	$	2,168,902	$	172,991	$	2,341,893

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,092,852	$	154,552	$	2,247,404
International OTC Healthcare	76,050		18,439		94,489

Intangible assets, net – March 31, 2023	$	2,168,902	$	172,991	$	2,341,893


	Year Ended March 31, 2022
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2021	$	2,281,988	$	389,347	$	2,671,335
Additions (a)	195,900		47,642		243,542


Tradename impairment	—		(1,700)		(1,700)
Effects of foreign currency exchange rates	(1,329)		885		(444)
Balance – March 31, 2022	$	2,476,559	$	436,174	$	2,912,733

Accumulated Amortization
Balance – March 31, 2021	$	—	$	195,606	$	195,606
Additions	—		21,499		21,499
Tradename impairment	—		(983)		(983)
Effects of foreign currency exchange rates	—		(24)		(24)
Balance – March 31, 2022	$	—	$	216,098	$	216,098

Intangible assets, net – March 31, 2022	$	2,476,559	$	220,076	$	2,696,635

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,391,517	$	198,353	$	2,589,870
International OTC Healthcare	85,042		21,723		106,765

Intangible assets, net – March 31, 2022	$	2,476,559	$	220,076	$	2,696,635

(a) On July 1, 2021, we completed the acquisition of certain assets from Akorn (see Note 2) and on December 15, 2021, our Australian subsidiary acquired the rights to the Zaditen brand in certain territories from Novartis Pharma AG. In connection with these acquisitions, we allocated $225.4 million to intangible assets for Akorn and $18.1 million for Zaditen.

Schedule of Expected Amortization Expense

At March 31, 2023, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which ranges from a period of 10 to 25 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):


(In thousands)
Year Ending March 31,	Amount
2024	$	19,784
2025	18,099
2026	16,149
2027	14,557
2028	12,221
Thereafter	92,181
	$	172,991